Latham & Watkins Advises Corvus Pharmaceuticals in Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, has announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,185,101 additional shares, at a price to the public of US$22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately US$201.2 million, including proceeds from the full exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock were offered by Corvus. 

Latham & Watkins LLP represented Corvus Pharmaceuticals in the transaction with a corporate team led by Bay Area partner Kathleen M. Wells, with associates Annie E. Kim and Edwin Gonzalez. Advice was also provided on healthcare regulatory matters by Bay Area partner Betty Pang and Washington, D.C. counsel Chad Jennings; and on tax matters by Bay Area partner Grace M. Lee, with associates Derek Gumm and Tessa Young.